Interactions and drug-metabolizing enzymes.
D000293:Adolescent; D000328:Adult; D018926:Anti-Allergic Agents / Q000009:adverse effects; D018687:Antidepressive Agents, Second-Generation; D000935:Antifungal Agents / Q000009:adverse effects; D001665:Binding Sites; D001711:Biotransformation; D065607:Cytochrome P-450 Enzyme Inhibitors; D003577:Cytochrome P-450 Enzyme System / Q000096:biosynthesis / Q000378:metabolism*; D004347:Drug Interactions; D064420:Drug-Related Side Effects and Adverse Reactions; D004790:Enzyme Induction; D004917:Erythromycin / Q000009:adverse effects / Q000494:pharmacology; D005260:Female; D005473:Fluoxetine / Q000009:adverse effects; D006801:Humans; D007527:Isoenzymes / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000378:metabolism*; D007654:Ketoconazole / Q000009:adverse effects; D008099:Liver / Q000201:enzymology* / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D004364:Pharmaceutical Preparations / Q000378:metabolism*; D016593:Terfenadine / Q000009:adverse effects; D013806:Theophylline / Q000037:antagonists & inhibitors; D016171:Torsades de Pointes / Q000139:chemically induced
D018926:Anti-Allergic Agents; D018687:Antidepressive Agents, Second-Generation; D000935:Antifungal Agents; D065607:Cytochrome P-450 Enzyme Inhibitors; D007527:Isoenzymes; D004364:Pharmaceutical Preparations; D005473:Fluoxetine; D004917:Erythromycin; D016593:Terfenadine; D003577:Cytochrome P-450 Enzyme System; D013806:Theophylline; D007654:Ketoconazole